---
document_datetime: 2025-05-13 14:25:25
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/actelsar-hct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: actelsar-hct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5233568
conversion_datetime: 2025-12-28 09:52:23.787599
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Actelsar HCT

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 08/05/2025                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000248682   | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted To update section 4.8 of the SmPC in accordance with the \"Guideline on fixed combination medicinal products,\". I addition the MAH took the opportunity to implement editorial change in the SmPC, Labelling and Annex II in line with the reference product and to bring the annexes in line with QRD. Furthermore, sections 4.2, 4.3, 4.4, 4.5 and 5.2 of the SmPC were updated to align with the reference labels of both active substances. Also section 4.7 of the SmPC was updated to replace the term \"drowsiness\" by \"syncope or vertigo\" to align with the adverse reactions table in section 4.8. The package leaflet is updated with the   | II and PL   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000245790   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted   | 23/01/2025   | SmPC and PL   |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|